JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

13.77 0.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.29

Максимум

14.21

Ключови измерители
By Trading Economics
Приходи	13M -72M
Продажби	18M 38M
Марж на печалбата	-189.28
Служители	270
EBITDA	20M -64M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+155.47% upside

Дивиденти
By Dow Jones
Следващи печалби	3.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	236M 1.1B
Предишно отваряне	13.48
Предишно затваряне	13.77

Настроения в новините

By Acuity

20%

80%

35 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.11.2025 г., 22:13 ч. UTC

Печалби

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2.11.2025 г., 21:23 ч. UTC

Печалби

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2.11.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2.11.2025 г., 23:34 ч. UTC

Пазарно говорене

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2.11.2025 г., 21:00 ч. UTC

Печалби

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2.11.2025 г., 21:00 ч. UTC

Печалби

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2.11.2025 г., 21:00 ч. UTC

Печалби

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2.11.2025 г., 20:55 ч. UTC

Печалби

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2.11.2025 г., 20:55 ч. UTC

Печалби

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2.11.2025 г., 20:55 ч. UTC

Печалби

Westpac FY Business Lending Up 15% on Year>WBC.AU

2.11.2025 г., 20:46 ч. UTC

Печалби

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2.11.2025 г., 20:46 ч. UTC

Печалби

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2.11.2025 г., 20:45 ч. UTC

Печалби

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2.11.2025 г., 20:44 ч. UTC

Печалби

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2.11.2025 г., 20:43 ч. UTC

Печалби

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2.11.2025 г., 20:42 ч. UTC

Печалби

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2.11.2025 г., 20:41 ч. UTC

Печалби

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2.11.2025 г., 20:40 ч. UTC

Печалби

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2.11.2025 г., 20:39 ч. UTC

Печалби

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2.11.2025 г., 20:37 ч. UTC

Печалби

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2.11.2025 г., 20:37 ч. UTC

Печалби

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2.11.2025 г., 20:37 ч. UTC

Печалби

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2.11.2025 г., 20:36 ч. UTC

Печалби

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2.11.2025 г., 20:35 ч. UTC

Печалби

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2.11.2025 г., 20:35 ч. UTC

Печалби

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2.11.2025 г., 20:35 ч. UTC

Печалби

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2.11.2025 г., 20:34 ч. UTC

Печалби

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2.11.2025 г., 20:33 ч. UTC

Печалби

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2.11.2025 г., 14:27 ч. UTC

Печалби

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2.11.2025 г., 14:25 ч. UTC

Печалби

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

155.47% нагоре

12-месечна прогноза

Среден 35 USD 155.47%

Висок 56 USD

Нисък 17 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

35 / 373 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.